Pangaea Oncology S.A. - Asset Resilience Ratio
Pangaea Oncology S.A. (PANG) has an Asset Resilience Ratio of 3.71% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Pangaea Oncology S.A.'s Asset Resilience Ratio has changed over time. Check Pangaea Oncology S.A. (PANG) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Pangaea Oncology S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Pangaea Oncology S.A. (PANG) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.10 Million | 3.71% |
| Total Liquid Assets | €1.10 Million | 3.71% |
Asset Resilience Insights
- Limited Liquidity: Pangaea Oncology S.A. maintains only 3.71% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pangaea Oncology S.A. Industry Peers by Asset Resilience Ratio
Compare Pangaea Oncology S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060 |
Diagnostics & Research | 2.10% |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439 |
Diagnostics & Research | 7.27% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Check Cap Ltd
NASDAQ:CHEK |
Diagnostics & Research | 70.29% |
|
BGI Genomics Co Ltd
SHE:300676 |
Diagnostics & Research | 3.62% |
Annual Asset Resilience Ratio for Pangaea Oncology S.A. (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Pangaea Oncology S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.39% | €1.10 Million ≈ $1.28 Million |
€32.41 Million ≈ $37.89 Million |
-1.50pp |
| 2023-12-31 | 4.88% | €1.41 Million ≈ $1.65 Million |
€28.83 Million ≈ $33.71 Million |
-25.12pp |
| 2022-12-31 | 30.01% | €8.51 Million ≈ $9.95 Million |
€28.38 Million ≈ $33.18 Million |
+15.94pp |
| 2021-12-31 | 14.06% | €2.93 Million ≈ $3.43 Million |
€20.85 Million ≈ $24.38 Million |
+12.32pp |
| 2020-12-31 | 1.75% | €299.85K ≈ $350.55K |
€17.17 Million ≈ $20.08 Million |
-3.15pp |
| 2019-12-31 | 4.90% | €826.59K ≈ $966.37K |
€16.88 Million ≈ $19.73 Million |
+1.20pp |
| 2018-12-31 | 3.69% | €751.56K ≈ $878.65K |
€20.35 Million ≈ $23.79 Million |
-1.60pp |
| 2017-12-31 | 5.30% | €1.00 Million ≈ $1.17 Million |
€18.96 Million ≈ $22.16 Million |
+2.91pp |
| 2016-12-31 | 2.39% | €428.47K ≈ $500.93K |
€17.94 Million ≈ $20.97 Million |
+2.08pp |
| 2015-12-31 | 0.31% | €34.34K ≈ $40.15K |
€11.01 Million ≈ $12.87 Million |
+0.29pp |
| 2014-12-31 | 0.02% | €1.75K ≈ $2.05K |
€8.46 Million ≈ $9.89 Million |
-0.04pp |
| 2013-12-31 | 0.06% | €3.75K ≈ $4.38K |
€6.54 Million ≈ $7.64 Million |
-- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vi… Read more